Haemonetics Co. (NYSE:HAE) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. trimmed its holdings in Haemonetics Co. (NYSE:HAE) by 6.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 81,432 shares of the medical instruments supplier’s stock after selling 5,543 shares during the period. Corebridge Financial Inc. owned 0.16% of Haemonetics worth $6,358,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Cerity Partners LLC increased its stake in shares of Haemonetics by 31.1% during the 3rd quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier’s stock worth $712,000 after purchasing an additional 2,102 shares in the last quarter. FMR LLC lifted its position in Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after buying an additional 521,640 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Haemonetics by 174.5% in the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 10,774 shares during the last quarter. Captrust Financial Advisors grew its holdings in Haemonetics by 30.1% in the third quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 982 shares during the period. Finally, Paloma Partners Management Co acquired a new position in shares of Haemonetics in the 3rd quarter valued at $623,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Down 1.8 %

HAE opened at $63.03 on Friday. The firm has a market capitalization of $3.17 billion, a P/E ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43. The firm’s 50 day moving average is $66.05 and its 200-day moving average is $74.68. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 52-week low of $58.80 and a 52-week high of $97.97.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on HAE shares. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC cut their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, JMP Securities decreased their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.